AdaptHealth delivers 64% return after Fair Value identified opportunity
InvestingPro's Fair Value models identified AdaptHealth Corp. (NASDAQ:AHCO) as significantly undervalued in February 2024, leading to a 63.81% return for investors who recognized the opportunity. The company, a provider of home healthcare equipment, was trading at $7.24 per share and has since risen to $12.03, surpassing its initial Fair Value target. This success highlights the effectiveness of fundamental value analysis in identifying mispriced stocks.
Why AdaptHealth (AHCO) Is Up 5.4% After Major Holders Buy Post-Earnings Dip – And What's Next
AdaptHealth (AHCO) saw its stock rise by 5.4% following significant purchases by major shareholders, including OEP VII GP, L.L.C. and ONE EQUITY PARTNERS, after a mixed Q4 2025 earnings report. These insiders invested nearly US$24.3 million, signaling confidence in the company's long-term strategy despite recent profitability challenges. The investment narrative for AdaptHealth revolves around contracts, automation, and demographic trends, with future growth potentially supported by acquisitions and overcoming regulatory uncertainties.
AHCO PE Ratio & Valuation, Is AHCO Overvalued
Adapthealth Corp (AHCO) is currently in the "Fair" valuation zone, with a forward PE ratio of 10.09, which is considered fair compared to its five-year average of 13.31. Its fair price is estimated to be between $11.37 and $20.32 based on a relative valuation method. Despite a P/S ratio of 0.44, which is significantly below the industry average, the company's robust revenue growth of -1.21% suggests this premium might be unsustainable.
Adapthealth Corp stock hits 52-week high at $11.77
Adapthealth Corp (AHCO) has reached a new 52-week high of $11.77, marking a 63% increase from its 52-week low. This surge reflects investor confidence and the company's steady growth, despite a recent significant shortfall in Q4 2025 EPS, as its revenue slightly exceeded forecasts. Analysts still maintain an Outperform rating, noting underlying progress.
[Form 4/A] AdaptHealth Corp. Amended Insider Trading Activity
This article details an amended Form 4 filing for AdaptHealth Corp. (AHCO) concerning insider trading activity by entities affiliated with One Equity Partners. The filing reports open-market purchases of common stock totaling 447,827 shares for approximately $4.44 million in late March 2026. The amendment clarifies the reporting persons and their direct/indirect holdings, originally filed by Richard Cashin, and now includes several One Equity Partners funds.
Adapthealth sees $4.4 million in purchases by OEP entities
Entities associated with One Equity Partners (OEP) recently acquired $4.4 million worth of AdaptHealth Corp. (NASDAQ: AHCO) shares in two transactions on March 19 and March 20, 2026. These purchases, made at prices between $9.81 and $9.95, significantly increased OEP's holdings to over 16.3 million shares. Despite a recent EPS miss in Q4 2025, analysts maintain an "Outperform" rating on AHCO, with InvestingPro suggesting the stock is undervalued.
Adapthealth corp. (AHCO) sees $19.9 million in purchases By Investing.com
AdaptHealth Corp. (AHCO) recently saw several entities, including OEP VII GP, L.L.C. and ONE EQUITY PARTNERS, purchase $19.9 million worth of common stock between March 10 and March 12, 2026. These purchases occurred while the stock trades near its 52-week high, with InvestingPro suggesting a fair value of $15.50, indicating it remains undervalued. This news follows AdaptHealth's mixed Q4 2025 earnings, where EPS significantly missed expectations but revenue slightly beat forecasts, leading to maintained "Outperform" ratings from Leerink Partners and RBC Capital despite adjusted price targets.
AdaptHealth Corp. (NASDAQ:AHCO) Short Interest Up 22.5% in March
AdaptHealth Corp. (NASDAQ:AHCO) experienced a significant 22.5% increase in short interest during March, with shorted shares reaching over 9 million by March 13th, representing 6.8% of outstanding shares. This rise in bearish sentiment follows AdaptHealth missing Q4 earnings per share estimates, though revenue surpassed forecasts. Despite mixed analyst ratings, a Wall Street consensus of "Moderate Buy" remains, with an average price target of $13.25, and a major shareholder recently increased their stake.
Precision Trading with Adapthealth Corp. (AHCO) Risk Zones
This article provides an in-depth analysis of Adapthealth Corp. (AHCO) using AI-generated signals for precision trading. It highlights strong sentiment indicators across all time horizons, supporting an overweight bias, despite elevated downside risk due to a lack of additional long-term support signals. The analysis includes specific institutional trading strategies, such as position trading, momentum breakout, and risk hedging, complete with entry zones, targets, and stop losses.
AHCO SEC Filings - Adapthealth Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Adapthealth Corp (AHCO) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. It highlights recent filings from 2025, detailing insider stock grants, equity compensation plan updates, and material event reports, all accompanied by AI-powered summaries and impact analysis. The platform tracks 43 SEC filings for AHCO and offers tools for investors to monitor regulatory disclosures and financial performance.
AHCO or SYK: Which Is the Better Value Stock Right Now?
This article evaluates whether AdaptHealth Corp. (AHCO) or Stryker Corporation (SYK) is a better value stock. It likely compares key financial metrics, market performance, and growth prospects for both companies to determine which offers a more compelling investment opportunity based on value investing principles.
AdaptHealth Corp. (AHCO) Lags Q2 Earnings and Revenue Estimates
The article states that AdaptHealth Corp. (AHCO) missed its Q2 earnings and revenue estimates. No further details are provided in the given incomplete content.
AHCO SEC Filings - Adapthealth Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Adapthealth Corp.'s (AHCO) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights recent filings detailing financial results, guidance updates, asset dispositions, and a new capitated partnership, along with insider transaction reports. The platform offers AI-powered summaries to help investors quickly identify key information within these regulatory documents.
Adapthealth stock hits 52-week high at 11.18 USD
Adapthealth Corp's stock has reached a new 52-week high of $11.18, trading at $11.16 with a market capitalization of $1.52 billion, demonstrating strong momentum with a 16% gain over the past six months. Despite a significant Q4 2025 EPS miss, revenue slightly exceeded forecasts, and InvestingPro analysis suggests the stock is undervalued with a Fair Value of $13.79, positioning it as a promising opportunity. Analysts maintain mixed sentiments but expect profitability this year, with RBC Capital reiterating an Outperform rating and Leerink Partners adjusting its price target while also keeping an Outperform rating.
Adapthealth stock hits 52-week high at 11.18 USD By Investing.com
AdaptHealth Corp.'s stock has reached a new 52-week high of $11.18 USD, trading at $11.16 USD with strong momentum, gaining 16% over six months. Despite a significant Q4 2025 EPS miss, the company beat revenue expectations, and InvestingPro analysis suggests the stock is undervalued with a fair value of $13.79 USD. Analysts maintain Outperform ratings, with price targets ranging from $12.00 to $13.00, reflecting confidence in its growth potential and anticipated profitability this year.
Monday’s insider activity: Major buys at AdaptHealth and Marketwise By Investing.com
This article details significant insider trading activities on Monday, March 24, 2026. It highlights major insider buys in AdaptHealth Corp, Marketwise, Inc., Rare Element Resources Ltd, Virtus Dividend, Interest & Premium Strategy Fund, and Kayne Anderson Energy Infrastructure Fund, Inc. Conversely, it reports substantial insider selling in Gitlab Inc., Powell Industries, Viper Energy, Inc., UWM Holdings Corp, and American Public Education Inc., providing transaction details and contextual stock performance.
AdaptHealth (NASDAQ:AHCO) Major Shareholder Acquires $4,430,761.00 in Stock
AdaptHealth (NASDAQ:AHCO) major shareholder Richard Cashin, Jr. acquired 447,100 shares worth over $4.43 million, increasing his stake by 2.82% to approximately 16.31 million shares. This transaction comes as AdaptHealth's shares traded up on Monday, with analysts maintaining a "Moderate Buy" rating despite the company missing its quarterly EPS estimates. The company, which provides home medical equipment, reported revenue slightly above estimates but a year-over-year decrease.
Adapthealth corp: Richard Cashin buys $4.4m in AHCO stock By Investing.com
Richard Cashin, a ten percent owner of AdaptHealth Corp (NASDAQ:AHCO), recently purchased 447,827 shares for approximately $4.4 million, increasing his total holdings to over 16.3 million shares. This insider buying occurs as AHCO stock trades near its 52-week high, despite the company reporting a significant EPS miss in Q4 2025 but exceeding revenue expectations. Analysts have maintained Outperform ratings, though some have lowered price targets due to recent financial performance and future projections.
AdaptHealth Corp. (NASDAQ:AHCO) Receives Consensus Rating of "Moderate Buy" from Analysts
AdaptHealth Corp. (NASDAQ:AHCO) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $13.25. Insider buying activity was noted, with a major shareholder purchasing over 689,000 shares recently. The company reported a Q4 EPS miss but revenue beat estimates, with the stock currently trading around $9.91.
Technical Reactions to AHCO Trends in Macro Strategies
This article provides a technical analysis of Adapthealth Corp. (NASDAQ: AHCO), highlighting strong sentiment across all horizons and an exceptional risk-reward setup. It outlines various AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The report emphasizes the predictive AI's capabilities in delivering opportunities, managing risk, and offers real-time signals for traders.
AdaptHealth Stock Jumps 9% As ‘One Equity Partners’ Discloses New Stake
AdaptHealth (AHCO) stock rose 9% after a major shareholder, Richard M. Cashin Jr. of One Equity Partners, purchased over two million shares for approximately $19.9 million. This significant insider buying signals confidence in the company, despite a recent volatile period and a disappointing Q4 earnings report. The company showed underlying progress with increased patient census, debt reduction, credit rating upgrades, and anticipates growth from a new capitated contract.
Is Insider Buying at AdaptHealth (AHCO) Reframing the Story on Automation, Contracts, and Consolidation?
AdaptHealth's major shareholder, Richard M. Cashin Jr., recently purchased an additional 2 million shares worth nearly US$20 million, significantly increasing his stake. This insider buying comes after a quarter where EPS missed expectations, yet revenue slightly exceeded forecasts, drawing attention to how informed shareholders are reacting to the company’s challenges. The article explores how this substantial insider buying might influence AdaptHealth's investment narrative, particularly concerning long-term contracts, automation, and consolidation, amidst current execution and reimbursement pressures, and a notable goodwill impairment.
Is Insider Buying at AdaptHealth (AHCO) Reframing the Story on Automation, Contracts, and Consolidation?
AdaptHealth's major shareholder, Richard M. Cashin Jr., recently purchased nearly US$20 million worth of additional shares, increasing his group's stake. This insider buying comes after AdaptHealth reported disappointing quarterly earnings but slightly exceeded revenue forecasts. The article explores how this significant insider investment may impact the company's long-term strategy focused on automation, contracts, and consolidation, especially in light of recent goodwill impairment and ongoing financial pressures.
Kennedy Capital Management LLC Increases Stock Holdings in AdaptHealth Corp. $AHCO
Kennedy Capital Management LLC significantly increased its stake in AdaptHealth Corp. ($AHCO) by 48.8% to over 2 million shares. This comes amidst mixed signals for AdaptHealth, including a quarterly EPS miss despite revenue beating estimates, and a "Moderate Buy" consensus rating from analysts with an average price target of $13.25. Additionally, a major shareholder, Richard M. Cashin Jr., also substantially increased his holdings, indicating strong insider confidence.
Thursday’s insider buys and sells: AdaptHealth leads activity
This article details significant insider trading activities for US stocks on Thursday, highlighting major purchases and sales by company executives and directors. AdaptHealth (AHCO) saw the largest insider purchase by a ten percent owner, while PBF Energy Inc. (PBF) experienced the biggest insider sale. The article also covers other notable transactions, providing financial data and analysis on the companies involved.
AdaptHealth (AHCO) Stock Soars—Key Information You Should Be Aware Of
AdaptHealth (AHCO) stock recently surged by 6.5% following a significant insider purchase by major shareholder Richard M. Cashin Jr., who acquired over two million shares for approximately $19.9 million. This move is seen as a strong indicator of confidence despite the company's recent volatile performance and a negative market reaction to its Q4 2025 earnings report. The stock is currently trading near its 52-week high, although its five-year performance shows a significant decline from initial investment value.
AdaptHealth (AHCO) Shares Skyrocket, What You Need To Know
Shares of AdaptHealth Corp. (AHCO) jumped 6.5% after a major shareholder, Richard M. Cashin Jr., disclosed the purchase of over two million shares for approximately $19.9 million, viewed as a strong vote of confidence. This comes despite the company recently reporting a significant loss in its fourth-quarter 2025 report, which overshadowed a revenue beat. AdaptHealth's stock has seen volatility but is up 8.1% year-to-date and is trading near its 52-week high.
Insider Buying: AdaptHealth (NASDAQ:AHCO) Major Shareholder Acquires 536,827 Shares of Stock
AdaptHealth (NASDAQ:AHCO) major shareholder Richard Cashin, Jr. recently acquired 536,827 shares of the company's stock for approximately $5.22 million, increasing his stake by 3.67% to a total of over 15 million shares. The stock traded flat at $9.75, with its 12-month range between $7.11 and $11.17, despite the company missing quarterly EPS estimates but exceeding revenue expectations. Institutional investors hold a significant portion of the stock, and analysts currently have a "Moderate Buy" rating with an average price target of $13.25.
AdaptHealth (AHCO) Stock Soars—Key Information You Should Be Aware Of
AdaptHealth Corp. (AHCO) saw its stock price increase by 6.5% following a significant insider purchase by major stakeholder Richard M. Cashin Jr., who acquired over two million shares for approximately $19.9 million. This surge comes after a period of volatility, including a 16.4% drop after disappointing Q4 2025 earnings despite beating revenue estimates. The stock is currently trading near its 52-week high, though its five-year performance indicates a substantial loss for long-term investors.
Adapthealth corp: Richard Cashin buys $19.9 million in AHCO stock
Richard Cashin Jr., a major shareholder in AdaptHealth Corp (AHCO), recently purchased $19.9 million worth of the company's stock, acquiring over 2 million shares between March 10 and March 12, 2026. This move comes as InvestingPro analysis suggests the stock is undervalued with strong financial indicators. This news follows AdaptHealth's Q4 2025 earnings report, which included an EPS miss but a revenue beat, leading to varying analyst ratings.
A Look At AdaptHealth (AHCO) Valuation After Loss-Making 2025 Results And Goodwill Impairment
AdaptHealth (AHCO) recently reported a shift from profit to a net loss for full-year 2025, alongside a significant goodwill impairment of US$127.99m. Despite these challenges and a decline in longer-term share performance, the company issued 2026 revenue guidance of US$3.44b to US$3.51b, suggesting future scale. Simply Wall St's analysis indicates AHCO is currently undervalued at $9.49 compared to a fair value of $17.00, driven by expectations of growth in tech-enabled care models, though risks like CMS reimbursement and execution challenges remain.
How Investors Are Reacting To AdaptHealth (AHCO) Raising 2026 Revenue Guidance Despite 2025 Net Loss
AdaptHealth Corp. reported a net loss of US$70.79 million for 2025, partly due to a goodwill impairment, but raised its 2026 net revenue guidance to US$3.44 billion to US$3.51 billion. The company is continuing to pursue home medical equipment acquisitions, funded in part by a US$100 million revolver draw, emphasizing growth and patient access. Investors are evaluating whether the increased revenue guidance and ongoing acquisitions can lead to cleaner earnings despite regulatory and integration risks and recurring goodwill impairments.
AdaptHealth Reports Fourth-Quarter, Full-Year 2025 Financial Results
AdaptHealth Corp. (Nasdaq: AHCO) reported a net loss for both the fourth quarter and full year of 2025, primarily due to a goodwill impairment charge, despite their efforts in restructuring operations and expanding contracts. The company's net revenue saw a slight decline for the full year, but cash flow from operations increased. Looking ahead to fiscal year 2026, AdaptHealth projects increased net revenue and adjusted EBITDA.
Trading the Move, Not the Narrative: (AHCO) Edition
This article provides an AI-generated analysis for Adapthealth Corp. (NASDAQ: AHCO), highlighting divergent sentiment and a mid-channel oscillation pattern. It outlines three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels. The report also includes multi-timeframe signal analysis indicating support and resistance levels for near-term, mid-term, and long-term horizons, and offers access to real-time signals and a personalized dashboard for tracking.
Vanguard Group Inc. Has $100.93 Million Stock Holdings in AdaptHealth Corp. $AHCO
Vanguard Group Inc. has scaled back its stake in AdaptHealth Corp. by 4.9% in the third quarter, now holding 11.28 million shares valued at approximately $100.93 million. This comes as AdaptHealth reported a significant earnings miss despite exceeding revenue estimates, leading to a negative net margin. The company currently has a "Moderate Buy" consensus rating from analysts, with institutional ownership remaining high at 82.67%.
Unpacking Q4 Earnings: AdaptHealth (NASDAQ:AHCO) In The Context Of Other Senior Health, Home Health & Hospice Stocks
AdaptHealth (NASDAQ:AHCO) reported Q4 revenues of $846.3 million, beating analyst estimates but missing EPS expectations. The broader senior health, home care, and hospice industries faced a slower Q4, with sector-wide revenues beating consensus by 1.1% but stock prices declining by an average of 7.4% since earnings. BrightSpring Health Services (NASDAQ:BTSG) delivered the strongest Q4 performance, while Chemed (NYSE:CHE) showed the weakest results against analyst estimates.
AdaptHealth Corp. (AHCO) Stock Analysis: Exploring a 33.56% Potential Upside in the Medical Devices Sector
AdaptHealth Corp. (AHCO), a significant player in the U.S. medical devices industry, presents an intriguing investment opportunity with a potential upside of 33.56% based on analysts' average target price of $12.88. Despite mixed financial signals like a revenue dip, the company boasts strong free cash flow and a predominantly positive outlook from the investment community. Its strategic position in Sleep, Respiratory, and Diabetes Health, coupled with diverse product offerings, positions it to capitalize on growing healthcare demands.
Segall Bryant & Hamill LLC Cuts Stock Position in AdaptHealth Corp. $AHCO
Segall Bryant & Hamill LLC significantly reduced its stake in AdaptHealth Corp. ($AHCO) by 8.2% in the third quarter, now owning 3.18% of the company's stock valued at $38.48 million. Other institutional investors showed mixed activity, with some increasing and others initiating positions. AdaptHealth reported disappointing Q3 earnings, missing consensus estimates, and analysts have issued varied ratings, with a consensus price target of $13.25.
Why AdaptHealth (AHCO) Is Down 9.7% After 2025 Loss, Impairment And 2026 Guidance Update – And What’s Next
AdaptHealth Corp. reported a significant net loss of US$70.79 million in 2025, partly due to a US$127.99 million goodwill impairment, leading to a 9.7% stock drop. Despite this, the company provided 2026 revenue guidance of US$3.44 billion to US$3.51 billion, driven by record patient volumes, a new large capitated contract, and recent acquisitions. The article highlights the importance of successful execution of the new capitated contract and the impact of CMS reimbursement decisions on AdaptHealth's future investment narrative.
Insider Buying: Rew Richard W. II Acquires Shares in AdaptHealth Corp (AHCO)
Rew Richard W. II, Chief Legal Officer and General Counsel at AdaptHealth Corp (AHCO), purchased 5,000 shares of the company's stock on February 26, 2026, increasing his total holdings to 107,097 shares. This transaction occurred when shares were trading at $8.91, indicating that AdaptHealth Corp is considered fairly valued based on its GuruFocus Value of $9.93. The company's price-earnings ratio of 16.64 is lower than both the industry median and its historical median.
Why AdaptHealth (AHCO) Is Down 9.7% After 2025 Loss, Impairment And 2026 Guidance Update – And What’s Next
AdaptHealth (AHCO) experienced a 9.7% stock drop following its full-year 2025 results, which included a net loss of US$70.79 million, a US$127.99 million goodwill impairment, and updated 2026 revenue guidance of US$3.44 billion to US$3.51 billion. The company is focusing on scale, value-based care, and portfolio concentration, with management highlighting record patient volumes and a new large capitated contract. Investors are now evaluating the execution risk associated with the new contract and the potential for continued margin pressure.
Why AdaptHealth (AHCO) Is Down 9.7% After 2025 Loss, Impairment And 2026 Guidance Update – And What’s Next
AdaptHealth Corp. reported a net loss of US$70.79 million in 2025, influenced by a US$127.99 million goodwill impairment, while forecasting 2026 revenue between US$3.44 billion and US$3.51 billion. The company attributes the loss to impairment and upfront spending for a new capitated contract, despite recording record patient volumes and new acquisitions. This has led to a focus on execution risk for the new contract and the impact of CMS reimbursement decisions on its future performance.
HALPER SADEH LLC ENCOURAGES ADAPTHEALTH CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of AdaptHealth Corp. (NASDAQ: AHCO) breached their fiduciary duties to shareholders. The firm encourages long-term AdaptHealth shareholders to contact them to discuss potential actions such as seeking corporate governance reforms, the return of funds to the company, or other relief. The firm handles such actions on a contingent fee basis, emphasizing that shareholder involvement can enhance transparency, accountability, and ultimately shareholder value.
AdaptHealth’s $12 Million Settlement: Strategic Positioning Ahead of the Final Approval Trigger
A federal judge in Pennsylvania has rejected a motion to dismiss a securities class action against AdaptHealth, clearing the way for a proposed $12 million settlement to proceed. The settlement, covering alleged misconduct between November 2019 and July 2021, is considered financially insignificant for AdaptHealth but highlights underlying concerns about misrepresentation of organic growth and billing practices. While the settlement resolves one issue, it may trigger further lawsuits and regulatory scrutiny, particularly regarding potential violations of Medicare and Medicaid billing regulations.
HALPER SADEH LLC ENCOURAGES ADAPTHEALTH CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of AdaptHealth Corp. (NASDAQ: AHCO) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders to contact them to discuss potential corporate governance reforms, recovery of funds, or other benefits. Shareholder involvement can lead to improved company policies and enhanced shareholder value.
AdaptHealth Corp. (NASDAQ:AHCO) Receives Average Recommendation of "Moderate Buy" from Analysts
AdaptHealth Corp. (NASDAQ:AHCO) has received a consensus "Moderate Buy" rating from analysts, with an average one-year price target of $14.25. Despite beating revenue expectations at $846.3 million, the company significantly missed EPS estimates, reporting $(0.76) against an expected $0.34, leading to increased near-term uncertainty due to ambiguous guidance. Institutional investors hold a substantial 82.67% of the stock, while insider activity showed a director selling 5,000 shares.
AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2025 Results
AdaptHealth Corp. has released its financial results for the fourth quarter and full-year 2025, reporting a net revenue of $3.24 billion for the full year and a net loss of $70.8 million, impacted by a goodwill impairment charge. Despite the financial decline, the company achieved patient census records, expanded geographically, and reduced its debt by $250 million in 2025. AdaptHealth also provided positive financial guidance for 2026, anticipating net revenue between $3.44 billion and $3.51 billion.
AdaptHealth Corp. SEC 10-K Report
AdaptHealth Corp. has released its 2025 Form 10-K report, revealing a total net revenue of $3,244.9 million, a 0.5% decrease from the previous year, and a net loss of $66.0 million due to goodwill impairment and increased costs. The company is strategically managing its portfolio through dispositions and acquisitions, focusing on technological advancements, and aiming to reduce debt and maintain strong liquidity. AdaptHealth faces significant operational, financial, cybersecurity, regulatory, and market risks, along with challenges from a competitive landscape and integration risks associated with its growth strategy.
Why AdaptHealth (AHCO) Stock Is Nosediving
AdaptHealth Corp.'s (AHCO) stock plummeted 16.4% after its Q4 2025 report revealed a significant loss of $0.76 per share, far missing analyst expectations for a profit, despite beating revenue forecasts. This poor profitability, marked by a negative operating margin and missed adjusted EBITDA, has led to increased stock volatility. The company's shares are currently trading 24.5% below its 52-week high, indicating a substantial negative market reaction to the earnings results.
AdaptHealth Corp. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:AHCO) 2026-02-24
AdaptHealth Corp. (AHCO) announced its Q4 2025 earnings, reporting an EPS of $0.27, which missed estimates by $0.07. However, the company's revenue reached $846.29M, surpassing expectations by $14.68M despite a 1.21% year-over-year decrease. This presentation summarizes the financial results from their recent earnings call.
